Citations (76)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Robert A. Copeland. (2021) Evolution of the drug-target residence time model. Expert Opinion on Drug Discovery 16:12, pages 1441-1451.
Read now
Read now
Walter Mandaliti, Ridvan Nepravishta, Francesca Pica, Paola Sinibaldi Vallebona, Enrico Garaci & Maurizio Paci. (2018) Potential mechanism of thymosin-α1-membrane interactions leading to pleiotropy: experimental evidence and hypotheses. Expert Opinion on Biological Therapy 18:sup1, pages 33-42.
Read now
Read now
Wilhelmus EA de Witte, Yin Cheong Wong, Indira Nederpelt, Laura H Heitman, Meindert Danhof, Piet H van der Graaf, Ron AHJ Gilissen & Elizabeth C.M. de Lange. (2016) Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients. Expert Opinion on Drug Discovery 11:1, pages 45-63.
Read now
Read now
Georges Vauquelin. (2015) On the ‘micro’-pharmacodynamic and pharmacokinetic mechanisms that contribute to long-lasting drug action. Expert Opinion on Drug Discovery 10:10, pages 1085-1098.
Read now
Read now
Georges Vauquelin & Isabelle Van Liefde. (2012) Radioligand dissociation measurements: potential interference of rebinding and allosteric mechanisms and physiological relevance of the biological model systems. Expert Opinion on Drug Discovery 7:7, pages 583-595.
Read now
Read now
Rumin Zhang & Frederick Monsma. (2010) Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs. Expert Opinion on Drug Discovery 5:11, pages 1023-1029.
Read now
Read now
Articles from other publishers (70)
Kevin E. Knockenhauer & Robert A. Copeland. (2023) The importance of binding kinetics and drug–target residence time in pharmacology. British Journal of Pharmacology.
Crossref
Crossref
Johan Gabrielsson & Stephan Hjorth. (2023) Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance. Pharmacological Reviews 75:3, pages 416-462.
Crossref
Crossref
Xiaoke Gu, Haoxing Yuan, Wenchao Zhao, Nan Sun, Wenzhong Yan, Chunyu Jiang, Yan He, Hongli Liu, Jianjun Cheng & Dong Guo. (2022)
Optical-Controlled Kinetic Switch: Fine-Tuning of the Residence Time of an Antagonist Binding to the Vasopressin V
2
Receptor in
In Vitro
, Ex Vivo, and In Vivo Models of ADPKD
. Journal of Medicinal Chemistry 66:2, pages 1454-1466.
Crossref
Crossref
Hao-Yuan Wang, Haojun Yang, Mikael Holm, Harrison Tom, Keely Oltion, Amjad Ayad Qatran Al-Khdhairawi, Jean-Frédéric F. Weber, Scott C. Blanchard, Davide Ruggero & Jack Taunton. (2022) Synthesis and single-molecule imaging reveal stereospecific enhancement of binding kinetics by the antitumour eEF1A antagonist SR-A3. Nature Chemistry 14:12, pages 1443-1450.
Crossref
Crossref
Haoran Zhang, Wenzhong Yan, Yongzhan Sun, Haoxing Yuan, Limin Su, Xudong Cao, Peng Wang, Zhou Xu, Youhui Hu, Zhongjian Wang, Yinan Wang, Kequan Fu, Ying Sun, Yupeng Chen, Jianjun Cheng & Dong Guo. (2022)
Long Residence Time at the Vasopressin V
2
Receptor Translates into Superior Inhibitory Effects in
Ex Vivo
and
In Vivo
Models of Autosomal Dominant Polycystic Kidney Disease
. Journal of Medicinal Chemistry 65:11, pages 7717-7728.
Crossref
Crossref
Stefanie Alexandra Eberle & Martin Gustavsson. (2022) A Scintillation Proximity Assay for Real-Time Kinetic Analysis of Chemokine–Chemokine Receptor Interactions. Cells 11:8, pages 1317.
Crossref
Crossref
Charles S. Lay, Daniel A. Thomas, John P. Evans, Matthew Campbell, Kristopher McCombe, Alexander N. Phillipou, Laurie J. Gordon, Emma J. Jones, Kristin Riching, Mahnoor Mahmood, Cassie Messenger, Charlotte E. Carver, Kelly M. Gatfield & Peter D. Craggs. (2022) Development of an intracellular quantitative assay to measure compound binding kinetics. Cell Chemical Biology 29:2, pages 287-299.e8.
Crossref
Crossref
Callum J Dickson, Viktor Hornak & Jose S Duca. (2021) Relative Binding Free-Energy Calculations at Lipid-Exposed Sites: Deciphering Hot Spots. Journal of Chemical Information and Modeling 61:12, pages 5923-5930.
Crossref
Crossref
Charles S Lay, Daniel A Thomas & Peter D Craggs. (2021) Kinetic intracellular assay measures compound binding kinetics at intracellular targets within living cells. Future Drug Discovery 3:4.
Crossref
Crossref
Tomasz Róg, Mykhailo Girych & Alex Bunker. (2021) Mechanistic Understanding from Molecular Dynamics in Pharmaceutical Research 2: Lipid Membrane in Drug Design. Pharmaceuticals 14:10, pages 1062.
Crossref
Crossref
Gonçalo S. Clemente, Inês F. Antunes, Santosh Kurhade, Mariska P.M. van den Berg, Jürgen W.A. Sijbesma, Aren van Waarde, Rogier C. Buijsman, Nicole Willemsen-Seegers, Reinoud Gosens, Herman Meurs, Alexander Dömling & Philip H. Elsinga. (2021)
Mapping Arginase Expression with
18
F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary α-Amino Acids
. Journal of Nuclear Medicine 62:8, pages 1163-1170.
Crossref
Crossref
Robert A. Copeland. (2021) Chance Favors the Perplexed Mind: The Critical Role of Mechanistic Biochemistry in Drug Discovery. Biochemistry 60:29, pages 2275-2284.
Crossref
Crossref
Haiyang Yang, Xueyan Li, Gang Li, Huating Huang, Wenning Yang, Xiaoquan Jiang, Muli Sen, Jingjing Liu, Yang Liu, Yanli Pan & Guopeng Wang. (2021) Accurate quantitative determination of affinity and binding kinetics for tight binding inhibition of xanthine oxidase. Biomedicine & Pharmacotherapy 139, pages 111664.
Crossref
Crossref
Paulo C. T. Souza, Vittorio Limongelli, Sangwook Wu, Siewert J. Marrink & Luca Monticelli. (2021) Perspectives on High-Throughput Ligand/Protein Docking With Martini MD Simulations. Frontiers in Molecular Biosciences 8.
Crossref
Crossref
Susanne Röhl, Marcus Weber & Konstantin Fackeldey. (2021) Computing the Minimal Rebinding Effect for NonReversible Processes. Multiscale Modeling & Simulation 19:1, pages 460-477.
Crossref
Crossref
Jerome H. Hochman. (2021) Adapting ADME and Pharmacokinetic Analysis to the Next Generation of Therapeutic Modalities. Journal of Pharmaceutical Sciences 110:1, pages 35-41.
Crossref
Crossref
David A. Sykes, Leire Borrega-Roman, Clare R. Harwood, Bradley Hoare, Jack M. Lochray, Thais Gazzi, Stephen J. Briddon, Marc Nazaré, Uwe Grether, Stephen J. Hill, Steven J. Charlton & Dmitry B. Veprintsev. 2021. Biophysical and Computational Tools in Drug Discovery. Biophysical and Computational Tools in Drug Discovery
1
32
.
Doris A. Schuetz, Lars Richter, Riccardo Martini & Gerhard F. Ecker. (2020) A structure–kinetic relationship study using matched molecular pair analysis. RSC Medicinal Chemistry 11:11, pages 1285-1294.
Crossref
Crossref
Hiroyuki Takita, Adam S. Darwich, Amais Ahmad & Amin Rostami‐Hodjegan. (2020) Application of the Nested Enzyme‐Within‐Enterocyte (NEWE) Turnover Model for Predicting the Time Course of Pharmacodynamic Effects. CPT: Pharmacometrics & Systems Pharmacology 9:11, pages 617-627.
Crossref
Crossref
Oksana A. Lenina, Irina V. Zueva, Vladimir V. Zobov, Vyacheslav E. Semenov, Patrick Masson & Konstantin A. Petrov. (2020) Slow-binding reversible inhibitor of acetylcholinesterase with long-lasting action for prophylaxis of organophosphate poisoning. Scientific Reports 10:1.
Crossref
Crossref
D. V. Borisov & A.V. Veselovsky. (2020) Ligand–Receptor Binding Kinetics in Drug Design. Biochemistry (Moscow), Supplement Series B: Biomedical Chemistry 14:3, pages 228-240.
Crossref
Crossref
Carrow I. Wells, James D. Vasta, Cesear R. Corona, Jennifer Wilkinson, Chad A. Zimprich, Morgan R. Ingold, Julie E. Pickett, David H. Drewry, Kathryn M. Pugh, Marie K. Schwinn, Byounghoon Hwang, Hicham Zegzouti, Kilian V. M. Huber, Mei Cong, Poncho L. Meisenheimer, Timothy M. Willson & Matthew B. Robers. (2020) Quantifying CDK inhibitor selectivity in live cells. Nature Communications 11:1.
Crossref
Crossref
Wijnand J. C. van der Velden, Laura H. Heitman & Mette M. Rosenkilde. (2020) Perspective: Implications of Ligand–Receptor Binding Kinetics for Therapeutic Targeting of G Protein-Coupled Receptors. ACS Pharmacology & Translational Science 3:2, pages 179-189.
Crossref
Crossref
D.V. Borisov & A.V. Veselovsky. (2020) Ligand-receptor binding kinetics in drug design. Biomeditsinskaya Khimiya 66:1, pages 42-53.
Crossref
Crossref
Christopher T. Szlenk, Jeevan B. GC & Senthil Natesan. (2019) Does the Lipid Bilayer Orchestrate Access and Binding of Ligands to Transmembrane Orthosteric/Allosteric Sites of G Protein-Coupled Receptors?. Molecular Pharmacology 96:5, pages 527-541.
Crossref
Crossref
Adriaan P. IJzerman & Dong Guo. (2019) Drug–Target Association Kinetics in Drug Discovery. Trends in Biochemical Sciences 44:10, pages 861-871.
Crossref
Crossref
Kin Sing Stephen Lee, Jun Yang, Jun Niu, Connie J. Ng, Karen M. Wagner, Hua Dong, Sean D. Kodani, Debin Wan, Christophe Morisseau & Bruce D. Hammock. (2019)
Drug-Target Residence Time Affects
in Vivo
Target Occupancy through Multiple Pathways
. ACS Central Science 5:9, pages 1614-1624.
Crossref
Crossref
David A. Sykes, Leigh A. Stoddart, Laura E. Kilpatrick & Stephen J. Hill. (2019) Binding kinetics of ligands acting at GPCRs. Molecular and Cellular Endocrinology 485, pages 9-19.
Crossref
Crossref
Pascal Zihlmann, Marleen Silbermann, Timothy Sharpe, Xiaohua Jiang, Tobias Mühlethaler, Roman P. Jakob, Said Rabbani, Christoph P. Sager, Priska Frei, Lijuan Pang, Timm Maier & Beat Ernst. (2018) KinITC-One Method Supports both Thermodynamic and Kinetic SARs as Exemplified on FimH Antagonists. Chemistry - A European Journal 24:49, pages 13049-13057.
Crossref
Crossref
Konstantin A. Petrov, Evgeny E. Nikolsky & Patrick Masson. (2018) Autoregulation of Acetylcholine Release and Micro-Pharmacodynamic Mechanisms at Neuromuscular Junction: Selective Acetylcholinesterase Inhibitors for Therapy of Myasthenic Syndromes. Frontiers in Pharmacology 9.
Crossref
Crossref
Doris A. Schuetz, Lars Richter, Marta Amaral, Melanie Grandits, Ulrich Grädler, Djordje Musil, Hans-Peter Buchstaller, Hans-Michael Eggenweiler, Matthias Frech & Gerhard F. Ecker. (2018) Ligand Desolvation Steers On-Rate and Impacts Drug Residence Time of Heat Shock Protein 90 (Hsp90) Inhibitors. Journal of Medicinal Chemistry 61:10, pages 4397-4411.
Crossref
Crossref
Georges Vauquelin. (2018)
Link between a high
k
on
for drug binding and a fast clinical action: to be or not to be?
. MedChemComm 9:9, pages 1426-1438.
Crossref
Crossref
Rutger H.A. Folmer. (2018) Drug target residence time: a misleading concept. Drug Discovery Today 23:1, pages 12-16.
Crossref
Crossref
Georges Vauquelin. (2017)
Distinct
in vivo
target occupancy by bivalent- and induced-fit-like binding drugs
. British Journal of Pharmacology 174:23, pages 4233-4246.
Crossref
Crossref
W.E.A. de Witte, G. Vauquelin, P.H. van der Graaf & E.C.M. de Lange. (2017) The influence of drug distribution and drug-target binding on target occupancy: The rate-limiting step approximation. European Journal of Pharmaceutical Sciences 109, pages S83-S89.
Crossref
Crossref
Si Yan, Duncan E. Shaw, Linhong Yang, David A. Sandham, Mark P. Healy, John Reilly & Bing Wang. (2017) Interactions between β2-Adrenoceptor Ligands and Membrane: Atomic-Level Insights from Magic-Angle Spinning NMR. Journal of Medicinal Chemistry 60:16, pages 6867-6879.
Crossref
Crossref
Doris A. Schuetz, Wilhelmus Egbertus Arnout de Witte, Yin Cheong Wong, Bernhard Knasmueller, Lars Richter, Daria B. Kokh, S. Kashif Sadiq, Reggie Bosma, Indira Nederpelt, Laura H. Heitman, Elena Segala, Marta Amaral, Dong Guo, Dorothee Andres, Victoria Georgi, Leigh A. Stoddart, Steve Hill, Robert M. Cooke, Chris De Graaf, Rob Leurs, Matthias Frech, Rebecca C. Wade, Elizabeth Cunera Maria de Lange, Adriaan P. IJzerman, Anke Müller-Fahrnow & Gerhard F. Ecker. (2017) Kinetics for Drug Discovery: an industry-driven effort to target drug residence time. Drug Discovery Today 22:6, pages 896-911.
Crossref
Crossref
Wilhelmus E.A. de Witte, Meindert Danhof, Piet H. van der Graaf & Elizabeth C.M. de Lange. (2016) In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant. Trends in Pharmacological Sciences 37:10, pages 831-842.
Crossref
Crossref
Mark Soave, Leigh A. Stoddart, Alastair Brown, Jeanette Woolard & Stephen J. Hill. (2016)
Use of a new proximity assay (NanoBRET) to investigate the ligand‐binding characteristics of three fluorescent ligands to the human
β
1
‐adrenoceptor expressed in HEK‐293 cells
. Pharmacology Research & Perspectives 4:5.
Crossref
Crossref
Georges Vauquelin. (2016)
Cell membranes… and how long drugs may exert beneficial pharmacological activity
in vivo
. British Journal of Clinical Pharmacology 82:3, pages 673-682.
Crossref
Crossref
Georges Vauquelin. (2016)
Effects of target binding kinetics on
in vivo
drug efficacy: k
off
, k
on
and rebinding
. British Journal of Pharmacology 173:15, pages 2319-2334.
Crossref
Crossref
Callum J. Dickson, Viktor Hornak, Camilo Velez-Vega, Daniel J. J. McKay, John Reilly, David A. Sandham, Duncan Shaw, Robin A. Fairhurst, Steven J. CharltonDavid A. SykesRobert A. Pearlstein & Jose S. Duca. (2016) Uncoupling the Structure–Activity Relationships of β2 Adrenergic Receptor Ligands from Membrane Binding. Journal of Medicinal Chemistry 59:12, pages 5780-5789.
Crossref
Crossref
Walter Mandaliti, Ridvan Nepravishta, Paola Sinibaldi Vallebona, Francesca Pica, Enrico Garaci & Maurizio Paci. (2016) Thymosin α1 Interacts with Exposed Phosphatidylserine in Membrane Models and in Cells and Uses Serum Albumin as a Carrier. Biochemistry 55:10, pages 1462-1472.
Crossref
Crossref
Robert A. Copeland. (2015) The drug–target residence time model: a 10-year retrospective. Nature Reviews Drug Discovery 15:2, pages 87-95.
Crossref
Crossref
R. Nepravishta, W. Mandaliti, P.S. Vallebona, F. Pica, E. Garaci & M. Paci. 2016. Thymosins. Thymosins
101
119
.
Matthew B. Robers, Melanie L. Dart, Carolyn C. Woodroofe, Chad A. Zimprich, Thomas A. Kirkland, Thomas Machleidt, Kevin R. Kupcho, Sergiy Levin, James R. Hartnett, Kristopher Zimmerman, Andrew L. Niles, Rachel Friedman Ohana, Danette L. Daniels, Michael Slater, Monika G. Wood, Mei Cong, Yi-Qiang Cheng & Keith V. Wood. (2015) Target engagement and drug residence time can be observed in living cells with BRET. Nature Communications 6:1.
Crossref
Crossref
Dong Guo, Laura H. Heitman & Adriaan P. IJzerman. (2015) The Role of Target Binding Kinetics in Drug Discovery. ChemMedChem 10:11, pages 1793-1796.
Crossref
Crossref
Georges Vauquelin, Isabelle Van Liefde & David C. Swinney. (2015) Radioligand binding to intact cells as a tool for extended drug screening in a representative physiological context. Drug Discovery Today: Technologies 17, pages 28-34.
Crossref
Crossref
Karolina Gherbi, Lauren T. May, Jillian G. Baker, Stephen J. Briddon & Stephen J. Hill. (2015)
Negative cooperativity across β
1
‐adrenoceptor homodimers provides insights into the nature of the secondary low‐affinity CGP 12177 β1‐adrenoceptor binding conformation
. The FASEB Journal 29:7, pages 2859-2871.
Crossref
Crossref
Grant K Walkup, Zhiping You, Philip L Ross, Eleanor K H Allen, Fereidoon Daryaee, Michael R Hale, John O'Donnell, David E Ehmann, Virna J A Schuck, Ed T Buurman, Allison L Choy, Laurel Hajec, Kerry Murphy-Benenato, Valerie Marone, Sara A Patey, Lena A Grosser, Michele Johnstone, Stephen G Walker, Peter J Tonge & Stewart L Fisher. (2015) Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nature Chemical Biology 11:6, pages 416-423.
Crossref
Crossref
Rumin Zhang. (2015) Which trails are your drugs taking?. Nature Chemical Biology 11:6, pages 382-383.
Crossref
Crossref
Georges Vauquelin. 2015. Thermodynamics and Kinetics of Drug Binding. Thermodynamics and Kinetics of Drug Binding
273
293
.
J. G. Baker, R. G. W. Proudman & S. J. Hill. (2014) Salmeterol's Extreme 2 Selectivity Is Due to Residues in Both Extracellular Loops and Transmembrane Domains. Molecular Pharmacology 87:1, pages 103-120.
Crossref
Crossref
Kwok-Wing Yiu, Chi-Kin Lee, Ka-Cheung Kwok & Nai-Ho Cheung. (2014) Measuring the Kinetics of the Binding of Xenoestrogens and Estrogen Receptor Alpha by Fluorescence Polarization. Environmental Science & Technology 48:19, pages 11591-11599.
Crossref
Crossref
Georges Vauquelin, Giampiero Bricca & Isabelle Van Liefde. (2014) Avidity and positive allosteric modulation/cooperativity act hand in hand to increase the residence time of bivalent receptor ligands. Fundamental & Clinical Pharmacology 28:5, pages 530-543.
Crossref
Crossref
Ross Corriden, Laura E. Kilpatrick, Barrie Kellam, Stephen J. Briddon & Stephen J. Hill. (2014)
Kinetic analysis of antagonist‐occupied adenosine‐A
3
receptors within membrane microdomains of individual cells provides evidence of receptor dimerization and allosterism
. The FASEB Journal 28:10, pages 4211-4222.
Crossref
Crossref
David A. Sykes, Cheryl Parry, John Reilly, Penny Wright, Robin A. Fairhurst & Steven J. Charlton. (2014)
Observed Drug-Receptor Association Rates Are Governed by Membrane Affinity: The Importance of Establishing “Micro-Pharmacokinetic/Pharmacodynamic Relationships” at the
β
2
-Adrenoceptor
. Molecular Pharmacology 85:4, pages 608-617.
Crossref
Crossref
Susan Lorey, Erik Fiedler, Anja Kunert, Jörg Nerkamp, Christian Lange, Markus Fiedler, Eva Bosse-Doenecke, Maren Meysing, Manja Gloser, Chris Rundfeldt, Una Rauchhaus, Ilka Hänssgen, Thomas Göttler, Arnd Steuernagel, Ulrike Fiedler & Ulrich Haupts. (2014) Novel Ubiquitin-derived High Affinity Binding Proteins with Tumor Targeting Properties. Journal of Biological Chemistry 289:12, pages 8493-8507.
Crossref
Crossref
M. Weber & K. Fackeldey. (2014) Computing the Minimal Rebinding Effect Included in a Given Kinetics. Multiscale Modeling & Simulation 12:1, pages 318-334.
Crossref
Crossref
Carsten Kroll, Rosalba Mansi, Friederike Braun, Stefanie Dobitz, Helmut R. Maecke & Helma Wennemers. (2013) Hybrid Bombesin Analogues: Combining an Agonist and an Antagonist in Defined Distances for Optimized Tumor Targeting. Journal of the American Chemical Society 135:45, pages 16793-16796.
Crossref
Crossref
Georges Vauquelin. (2013) Simplified models for heterobivalent ligand binding: when are they applicable and which are the factors that affect their target residence time. Naunyn-Schmiedeberg's Archives of Pharmacology 386:11, pages 949-962.
Crossref
Crossref
Zhenhui Qi, Christoph Schlaich & Christoph A. Schalley. (2013) Multivalency in the Gas Phase: H/D Exchange Reactions Unravel the Dynamic “Rock ’n’ Roll” Motion in Dendrimer-Dendrimer Complexes. Chemistry - A European Journal 19:44, pages 14867-14875.
Crossref
Crossref
Göran Dahl & Tomas Akerud. (2013) Pharmacokinetics and the drug–target residence time concept. Drug Discovery Today 18:15-16, pages 697-707.
Crossref
Crossref
Georges Vauquelin & Steven J Charlton. (2013) Exploring avidity: understanding the potential gains in functional affinity and target residence time of bivalent and heterobivalent ligands. British Journal of Pharmacology 168:8, pages 1771-1785.
Crossref
Crossref
Rumin Zhang & William T. Windsor. 2013. Antiviral Methods and Protocols. Antiviral Methods and Protocols
59
79
.
Huayun Deng, Chaoming Wang, Ming Su & Ye Fang. (2012) Probing Biochemical Mechanisms of Action of Muscarinic M3 Receptor Antagonists with Label-Free Whole Cell Assays. Analytical Chemistry 84:19, pages 8232-8239.
Crossref
Crossref
Georges Vauquelin, Sophie Bostoen, Patrick Vanderheyden & Philip Seeman. (2012) Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism. Naunyn-Schmiedeberg's Archives of Pharmacology 385:4, pages 337-372.
Crossref
Crossref
Georges Vauquelin. (2012) Determination of drug–receptor residence times by radioligand binding and functional assays: experimental strategies and physiological relevance. MedChemComm 3:6, pages 645.
Crossref
Crossref
Sara N??ez, Jennifer Venhorst & Chris G. Kruse. (2012) Target?drug interactions: first principles and their application to drug discovery. Drug Discovery Today 17:1-2, pages 10-22.
Crossref
Crossref
Heidi Demaegdt, Paul Gard, Jean-Paul De Backer, Aneta Lukaszuk, Erzs?bet Szemenyei, G?za T?th, Dirk Tourw?Georges Vauquelin. (2011) Binding of ?AT4 receptor? ligands to insulin regulated aminopeptidase (IRAP) in intact Chinese hamster ovary cells. Molecular and Cellular Endocrinology 339:1-2, pages 34-44.
Crossref
Crossref